IDT Share Price

Open 0.12 Change Price %
High 0.12 1 Day 0.00 0.00
Low 0.12 1 Week -0.01 -7.69
Close 0.12 1 Month -0.02 -14.29
Volume 10000 1 Year -0.18 -60.00
52 Week High 0.31
52 Week Low 0.11
IDT Important Levels
Resistance 2 0.12
Resistance 1 0.12
Pivot 0.12
Support 1 0.12
Support 2 0.12
ASX Australia Most Active Stocks
BTT 11.33 -5.50%
BTT 11.33 -5.50%
BTT 11.33 -5.50%
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
VKA 0.02 100.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
PMQ 0.03 50.00%
BNV 0.03 50.00%
TEG 0.05 25.00%
TEG 0.05 25.00%
TEG 0.05 25.00%
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
GDY 0.01 -50.00%
IMU 0.01 -50.00%

IDT Australia Ltd (ASX: IDT)

IDT Technical Analysis 5
As on 25th May 2017 IDT Share Price closed @ 0.12 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.20 & Strong Sell for SHORT-TERM with Stoploss of 0.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
IDT Target for May
1st Target up-side 0.16
2nd Target up-side 0.18
3rd Target up-side 0.19
1st Target down-side 0.12
2nd Target down-side 0.1
3rd Target down-side 0.09
IDT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
IDT Address
45 Wadhurst Drive
Boronia, VIC 3155
Phone: 61 3 9801 8888
Fax: 61 3 9801 8773
IDT Latest News
Unusual Activity Spotted in IDT Australia Ltd (IDT.AX)   Concord Register   - 24th May 17
IDT Australia Limited (ASX:IDT) Quant Investor Update   Ozark Times   - 23rd May 17
Value Composition in Focus For IDT Australia Limited (ASX:IDT)   TCT   - 22nd May 17
IDT Australia to pocket $15M from divesting clinical trial business   Proactive Investors Australia   - 31st Oct 16
PharmaVentures Advises IDT Australia on the Divestment of CMAX Clinical Trial ...   PR Newswire (press release)   - 28th Oct 16
IDT Australia Divests CMAX Clinical Trial Business to I'rom Group Co. Ltd   PR Newswire (press release)   - 28th Oct 16
IDT Australia Ltd to reveal transaction   Proactive Investors Australia   - 27th Oct 16
BRIEF-I'rom Group to buy CMAX Pty Ltd from IDT Australia   Reuters   - 25th Oct 16
IDT Australia Ltd achieves major milestone for its brain cancer drug   Proactive Investors Australia   - 14th Apr 16
IDT Australia penetrates massive US drug markets   Proactive Investors Australia   - 06th Oct 15
Interactive Technical Analysis Chart IDT Australia Ltd ( IDT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on IDT Australia Ltd
IDT Business Profile
IDT Australia Limited, a pharmaceutical contract manufacturing company, provides products, research and development, and other technical services for the pharmaceutical and allied industries primarily in Australia. It is involved in the development, scale-up, and production of high potency active pharmaceutical ingredients, cytotoxic active pharmaceutical ingredients, hormones, and toxic reagents. The company’s product portfolio comprises anti-cancer drugs, anti-psychotics, antibiotics, narcotics, and anti-inflammatory drugs. It also offers a range of specialist formulation development manufacturing, packaging, and dispensing services for new products and clinical trial supplies; manufactures active and placebo clinical trial supplies in various dosage forms, such as tablets, capsules, suspensions, liquids, and ointments; and consultancy services in the areas of blinding, randomization, code breaks, labeling, packaging, storage and distribution of drugs, and retrieval and disposal of supplies. In addition, the company provides support services for new drug development and scale-up projects through its laboratory facilities. Further, it offers a range of services comprising feasibility assessments; cost estimates; study conduct; project planning and management; protocol and informed consent development; preparation, submission, and tracking of ethics applications; CTN/CTX preparation and submission; case report form design; investigator selection; site selection; healthy subject recruiting; patient recruiting; adverse event recording and reporting; data entry and quality control; processing and sample storage; and commercial sponsorship for the design, implementation, and management of clinical studies. The company is based in Boronia, Australia.